Resverlogix Corp

RFS

Company Profile

  • Business description

    Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

  • Contact

    4820 Richard Road South West
    Suite 300
    CalgaryABT3E 6L1
    CAN

    T: +1 403 254-9252

    E: [email protected]

    https://www.resverlogix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    18

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,779.006.000.07%
CAC 407,665.9125.64-0.33%
DAX 4023,909.61123.61-0.51%
Dow JONES (US)44,094.77275.500.63%
FTSE 1008,760.9637.95-0.43%
HKSE24,072.28211.87-0.87%
NASDAQ20,369.7396.270.47%
Nikkei 22540,019.94467.45-1.15%
NZX 50 Index12,646.5643.740.35%
S&P 5006,204.9531.880.52%
S&P/ASX 2008,548.506.200.07%
SSE Composite Index3,444.4320.200.59%

Market Movers